Related Experiment Video

Updated: Jul 11, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

[Reprogramming of nuclear proteasomes in K562 cells undergoing apoptosis. II. Effect of anticancer drug doxorubicin]

A S Tsimokha, A G Mittenberg, I N Evteeva

    Tsitologiia
    |October 9, 2007
    PubMed

    Insights

    Doxorubicin treatment alters nuclear proteasomes in K562 cells, changing subunit composition, phosphorylation, and enzymatic activity during apoptosis. This reprogramming affects proteasome function in programmed cell death.

    Area of Science:

    • Cell Biology
    • Molecular Biology
    • Biochemistry

    Context:

    • The 26S proteasome is a crucial cellular machine for protein degradation.
    • Apoptosis, or programmed cell death, involves complex cellular regulatory mechanisms.
    • K562 cells are a human chronic myeloid leukemia cell line often used in cancer research.

    Purpose:

    • To investigate alterations in nuclear 26S proteasomes during doxorubicin-induced apoptosis in K562 cells.
    • To examine changes in proteasome subunit composition, phosphorylation status, and enzymatic activities.
    • To understand the functional reprogramming of nuclear proteasomes during programmed cell death.

    Summary:

    • Doxorubicin (DR) treatment of K562 cells induces apoptosis, revealing significant changes in nuclear 26S proteasomes.
    • Proteasomes from DR-treated cells exhibit altered subunit patterns and phosphorylation states (threonine and tyrosine).
    • Key enzymatic activities (trypsin-like, chymotrypsin-like, endoribonuclease) and specific subunits (zeta/alpha5, iota/alpha6) are modified, impacting RNase activity.

    Impact:

    • Provides the first evidence of nuclear proteasome reprogramming during apoptosis.
    • Demonstrates that proteasome composition, phosphorylation, and activity are dynamically regulated during programmed cell death.
    • Offers insights into potential therapeutic targets for modulating proteasome function in cancer treatment.

    Related Concept Videos

    The Intrinsic Apoptotic Pathway01:31

    The Intrinsic Apoptotic Pathway

    Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
    Introduction to Nuclear Reprogramming01:14

    Introduction to Nuclear Reprogramming

    Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
    The Extrinsic Apoptotic Pathway01:17

    The Extrinsic Apoptotic Pathway

    The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Anaphase Promoting Complex00:50

    Anaphase Promoting Complex

    The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...